5-Butylpyridine-2,3-diamine | 1321571-89-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-Butylpyridine-2,3-diamine
• CAS: 1321571-89-4
• 化学式: C₉H₁₅N₃
• 分子量: 165.238
• InChiKey: HMOAFKSDTSREML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  64.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-methoxypyridin-2-yl) propionic acid 、 5-Butylpyridine-2,3-diamine 在 polyphosphoric acid 作用下， 生成 6-butyl-2-[2-(4-methoxypyridin-2-yl)ethyl]-1H-imidazo[4,5-b]pyridine
  参考文献：
  名称：

  Novel nanomolar imidazo[4,5-b]pyridines as selective nitric oxide synthase (iNOS) inhibitors: SAR and structural insights

  摘要：

  Inducible arginine oxidation and subsequent NO production by correspondent synthase (iNOS) are important cellular answers to proinflammatory signals. Prolonged NO production has been proved in higher organisms to cause stroke or septic shock. Several classes of potent NOS inhibitors have been reported, most of them targeting the arginine binding site of the oxygenase domain. Here we disclose the SAR and the rational design of potent and selective iNOS inhibitors which may be useful as anti-inflammatory drugs. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.073

文献信息

• US3961063A
  申请人：——

  公开号：US3961063A

  公开（公告）日：1976-06-01
• US4000285A
  申请人：——

  公开号：US4000285A

  公开（公告）日：1976-12-28
• US4002761A
  申请人：——

  公开号：US4002761A

  公开（公告）日：1977-01-11
• Novel nanomolar imidazo[4,5-b]pyridines as selective nitric oxide synthase (iNOS) inhibitors: SAR and structural insights
  作者：Ulrich Grädler、Thomas Fuchß、Wolf-Rüdiger Ulrich、Rainer Boer、Andreas Strub、Christian Hesslinger、Céline Anézo、Kay Diederichs、Andrea Zaliani

  DOI：10.1016/j.bmcl.2011.05.073

  日期：2011.7

  Inducible arginine oxidation and subsequent NO production by correspondent synthase (iNOS) are important cellular answers to proinflammatory signals. Prolonged NO production has been proved in higher organisms to cause stroke or septic shock. Several classes of potent NOS inhibitors have been reported, most of them targeting the arginine binding site of the oxygenase domain. Here we disclose the SAR and the rational design of potent and selective iNOS inhibitors which may be useful as anti-inflammatory drugs. (C) 2011 Elsevier Ltd. All rights reserved.